Tumor-associated macrophages promote resistance of hepatocellular carcinoma cells against sorafenib by activating CXCR2 signaling

BACKGROUND: Sorafenib (SOR) is the first line treatment for advanced hepatocellular carcinoma (HCC), but resistance develops frequently. Tumor-associated macrophages (TAMs) have been reported to affect the progression of HCC. We therefore aimed to study the role of TAMs in promoting SOR resistance....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hao-Chen, Haung, Lin-Ya, Wang, Chih-Jung, Chao, Ying-Jui, Hou, Ya-Chin, Yen, Chia-Jui, Shan, Yan-Shen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677647/
https://www.ncbi.nlm.nih.gov/pubmed/36411463
http://dx.doi.org/10.1186/s12929-022-00881-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677647/
https://www.ncbi.nlm.nih.gov/pubmed/36411463
http://dx.doi.org/10.1186/s12929-022-00881-4

Ejemplares similares